NMPA’s Multinational Expert Panel Meeting Going Virtual

NMPA: More Access to Increase Patient Samples in Clinical Trial
March 23, 2020
NMPA V.S FDA — Regulatory Response to the Coronavirus (COVID-19) Pandemic
April 6, 2020

NMPA’s Multinational Expert Panel Meeting Going Virtual

A staff member screens arriving passengers with thermal scanners at Hankou railway station in Wuhan, in China's central Hubei province on January 21, 2020. - Asian countries on January 21 ramped up measures to block the spread of a new virus as the death toll in China rose to six and the number of cases surpassed 300, raising concerns in the middle of a major holiday travel rush. (Photo by - / AFP) / China OUT

The NMPA expert panel convening scientists, medical experts, government officials, manufacturer’s representatives and Clinical Research Organizations (CROs) from transcontinental locations is delivered online for the first time. The virtual conference is to weigh the available evidence and provide scientific and medical advice on the safety and efficacy of an imported Class III device represented by China Med Device, LLC.

Physical Meeting & Teleconference

Due to the outbreak of the novel Coronavirus (COVID-19), the physical meeting became Impossible. As the registration process progresses, China Med Device initiated the meeting and facilitated it, providing the virtual system assistance and coordinating the time between experts and officials.

The virtual meeting turns out to be a better option. The physical meetings usually cost three months to prepare. Countless written materials had to be printed. Experts and staff from different parties in the globe had to be gathered. With the meetings going virtual, the scientific opinions can be delivered to manufacturers more effectively and efficiently.

NMPA’s E-channel

Amid the COVID-19 crisis, China NMPA has taken many measures to utilize the E-channel:

  1. High-efficiency online office in China, covering Chinese regulatory authorities, hospitals, type testing centers and Human Genetic Resources (HGR) offices
  2. Suspend paper document registration and mandate E-submission
  3. Suspend face-to-face NMPA pre-consultations; Applicants shall call Center for Medical Device Evaluation (CMDE)
  4. Suspend face-to-face supplement phase evaluations; Applicants shall apply on CMDE website
  5. Suspend face-to-face meetings for Innovation Application, Priority Review, and Clinical Trial Application; Applicants shall contact CMDE and set up an E-meeting

Clinical side:

  1. Decreased paperwork for IRB/EC approval, HGR filing, local NMPA filing, etc. Sponsors must submit electronically and use an E-signature
  2. Transformed EC review, utilizing E-submission and remote meetings with committee members
  3. More frequent use of a database for patient registry and Adverse Event monitoring
  4. Increased remote supervision and decreased visits by CRO staff to cut down service fees
  5. More Electronic Data Capture (EDC) applied to medical device clinical trials instead of paper CRF, etc.

NMPA published the “Guideline on Expert Panel/ Public Advisory Meeting” on December 5, 2019. Please click HERE for our post.